Treatments
We provide quick summaries of each product with links to learn more. No deep dives — just all the bleeding options, in one place.
Hemophilia A
-
Product: Adnovate
-
Average Adult Half-life: 14.7 hours
-
Administration: Intravenous
-
First Approved in US: 2015
-
Derived From Human Blood: No
-
Derived From: Chinese Hamster Ovary (CHO) cells
-
Manufacturer: Takeda
-
Manufacturer Copay Assistance: $20,000
-
Product Assistance Program: Yes
-
-
Product: Eloctate
-
Average Adult Half-life: 19.7 hours
-
Administration: Intravenous
-
First Approved in US: 2014
-
Derived From Human Blood: No
-
Derived From: Human Embryonic Kidney (HEK) cell line
-
Manufacturer: Sanofi
-
Manufacturer Copay Assistance: $20,000
-
Product Assistance Program: Yes
-
-
Product: Altuviiio
-
Average Adult Half-life: 48.2 hours
-
Administration: Intravenous
-
First Approved in US: 2023
-
Derived From Human Blood: No
-
Derived From: Human Embryonic Kidney (HEK) cell line
-
Manufacturer: Sanofi
-
Manufacturer Copay Assistance: $20,000
-
Product Assistance Program: Yes
-
-
Product: Jivi
-
Average Adult Half-life: 17.9 hours
-
Administration: Intravenous
-
First Approved in US: 2018
-
Derived From Human Blood: No
-
Derived From: Baby Hamster Kidney (BHK) cell line
-
Manufacturer: Bayer
-
Manufacturer Copay Assistance: $20,000
-
Product Assistance Program: Yes
-
-
Product: Kovaltry
-
Average Adult Half-life: 14.2 hours
-
Administration: Intravenous
-
First Approved in US: 2016
-
Derived From Human Blood: No
-
Derived From: Baby Hamster Kidney (BHK) cell line
-
Manufacturer: Bayer
-
Manufacturer Copay Assistance: $20,000
-
Product Assistance Program: Yes
-
-
Product: Afstyla
-
Average Adult Half-life: 14.2 hours
-
Administration: Intravenous
-
First Approved in US: 2016
-
Derived From Human Blood: No
-
Derived From: Chinese Hamster Ovary (CHO) cells
-
Manufacturer: CSL Behring
-
Manufacturer Copay Assistance: $12,000
-
Product Assistance Program: Yes
-
-
Product: Nuwiq
-
Average Adult Half-life: 17.1 hours
-
Administration: Intravenous
-
First Approved in US: 2015
-
Derived From Human Blood: No
-
Derived From: Human Embryonic Kidney (HEK) cell line
-
Manufacturer: Octapharma
-
Manufacturer Copay Assistance: $12,000
-
Product Assistance Program: Yes
-
-
Product: Novoeight
-
Average Adult Half-life: 12.4 hours
-
Administration: Intravenous
-
First Approved in US: 2013
-
Derived From Human Blood: No
-
Derived From: Chinese Hamster Ovary (CHO) cells
-
Manufacturer: Novo Nordisk
-
Manufacturer Copay Assistance: $15,000
-
Product Assistance Program: Yes
-
-
Product: Esperoct
-
Average Adult Half-life: 21.7 hours
-
Administration: Intravenous
-
First Approved in US: 2019
-
Derived From Human Blood: No
-
Derived From: Chinese Hamster Ovary (CHO) cells
-
Manufacturer: Novo Nordisk
-
Manufacturer Copay Assistance: $15,000
-
Product Assistance Program: Yes
-
-
Product: Xyntha
-
Average Adult Half-life: 11.2 hours
-
Administration: Intravenous
-
First Approved in US: 2008
-
Derived From Human Blood: No
-
Derived From: Chinese Hamster Ovary (CHO) cells
-
Manufacturer: Pfizer
-
Manufacturer Copay Assistance: $12,000
-
Product Assistance Program: Yes
-
-
Product: Koate-DVI
-
Average Adult Half-life: 16.1 hours
-
Administration: Intravenous
-
First Approved in US: 1974
-
Derived From Human Blood: Yes
-
Derived From: Human Plasma
-
Manufacturer: Kedrion
-
Manufacturer Copay Assistance: $15,000
-
Product Assistance Program: No
-
-
Product: Humate-P
-
Average Adult Half-life: 12.2 hours
-
Administration: Intravenous
-
First Approved in US: 1986
-
Derived From Human Blood: Yes
-
Derived From: Human Plasma
-
Manufacturer: CSL Behring
-
Manufacturer Copay Assistance: $12,000
-
Product Assistance Program: Yes
-
-
Product: Wilate
-
Average Adult Half-life: 10.6 hours
-
Administration: Intravenous
-
First Approved in US: 2009
-
Derived From Human Blood: Yes
-
Derived From: Plasma
-
Manufacturer: Octapharma
-
Manufacturer Copay Assistance: $12,000
-
Product Assistance Program: Yes
-
-
Product: Alphanate
-
Average Adult Half-life: Factor VIII 17.9 hours VWD 7.7 hours
-
Administration: Intravenous
-
First Approved in US: 1978
-
Derived From Human Blood: Yes
-
Derived From: Human Plasma
-
Manufacturer: Grifols
-
Manufacturer Copay Assistance: For previously enrolled patients only
-
Product Assistance Program: Yes
-
Sub Q
Hemlibra
-
Dosing Frequency: Every 1, 2 or 4 weeks
-
Administration: Subcutaneous Injection
-
First Approved in US: 2017
-
Inhibitor Indication: Indicated for both inhibitors and non-inhibitor patients.
-
Derived From Human Blood: No
-
Type: Monoclonal Antibody
-
Manufacturer: Genentech
-
Manufacturer Copay Assistance: $15000
-
Manufacturer Product Assistance Program: Yes
Qfitlia
-
Dosing Frequency: Every 1 or 2 months
-
Administration: Subcutaneous Injection
-
First Approve: 2025
-
Inhibitor Indication: Indicated for both inhibitors and non-inhibitor patients.
-
Derived From Human Blood: No
-
Type: mRNA
-
Manufacturer: Sanofi
-
Manufacturer Copay Assistance: $20000
-
Manufacturer Product Assistance Program: Yes
Alhemo
-
Dosing Frequency: Daily
-
Administration: Subcutaneous Injection
-
First Approve: 2024
-
Inhibitor Indication: Indicated for inhibitors patients only.
-
Derived From Human Blood: No
-
Type: Monoclonal Antibody
-
Manufacturer: Novo Nordisk
-
Manufacturer Copay Assistance: $15000
-
Manufacturer Product Assistance Program: Yes
Hympavzi
-
Dosing Frequency: Every 7 days
-
Administration: Subcutaneous Injection
-
First Approve: 2024
-
Inhibitor Indication: Indicated for non-inhibitor patients only.
-
Derived From Human Blood: No
-
Type: Monoclonal Antibody
-
Manufacturer: Pfizer
-
Manufacturer Copay Assistance: $15000
-
Manufacturer Product Assistance Program: Yes
Gene Therapy
Roctavian
-
Average Factor VIII at 4 Years: 33.60%
-
Administration: One time infusion
-
Pre-existing antibodies to adeno-associated virus serotype 5 accessibility: Not Acceptable. Patients must test negative for adeno-associated virus serotype 5 to receive Roctavian.
-
Derived From Human Blood: No
-
Gene Therapy Type: Adeno-associated virus vector-based (AAV5)
-
Manufacturer: BioMarin
-
First Approved in US: 2023
-
Manufacturer Financial Assistance Program: Yes
Hemophilia B
-
Product: Idelvion
-
Average Adult Half-life: 104 hours
-
Administration: Intravenous
-
First Approved in US: 2016
-
Derived From Human Blood: No
-
Derived From: Chinese Hamster Ovary (CHO) cells
-
Manufacturer: CSL Behring
-
Manufacturer Copay Assistance: $12,000
-
Product Assistance Program: Yes
-
-
Product: Benefix
-
Average Adult Half-life: 22.4 hours
-
Administration: Intravenous
-
First Approved in US: 1997
-
Derived From Human Blood: No
-
Derived From: Chinese Hamster Ovary (CHO) cells
-
Manufacturer: Pfizer
-
Manufacturer Copay Assistance: $12,000
-
Product Assistance Program: Yes
-
-
Product: Alprolix
-
Average Adult Half-life: 86 hours
-
Administration: Intravenous
-
First Approved in US: 2014
-
Derived From Human Blood: No
-
Derived From: Human Embryonic Kidney (HEK) cell line
-
Manufacturer: Sanofi
-
Manufacturer Copay Assistance: $20,000
-
Product Assistance Program: Yes
-
-
Product: Ixinity
-
Average Adult Half-life: 24 hours
-
Administration: Intravenous
-
First Approved in US: 2015
-
Derived From Human Blood: No
-
Derived From: Chinese Hamster Ovary (CHO) cells
-
Manufacturer: Medexus
-
Manufacturer Copay Assistance: $12,000
-
Product Assistance Program: Yes
-
-
Product: Rebinyn
-
Average Adult Half-life: 115 hours
-
Administration: Intravenous
-
First Approved in US: 2017
-
Derived From Human Blood: No
-
Derived From: Chinese Hamster Ovary (CHO) cells
-
Manufacturer: Novo Nordisk
-
Manufacturer Copay Assistance: $15,000
-
Product Assistance Program:
-
-
Product: AlphaNine SD
-
Average Adult Half-life: 21 hours
-
Administration: Intravenous
-
First Approved in US: 1996
-
Derived From Human Blood: Yes
-
Derived From: Human plasma
-
Manufacturer: Grifols
-
Manufacturer Copay Assistance: No annual limits
-
Product Assistance Program: Yes
-
-
Product: Profilnine
-
Average Adult Half-life: 24.7 hours
-
Administration: Intravenous
-
First Approved in US: 1986
-
Derived From Human Blood: Yes
-
Derived From: Human plasma
-
Manufacturer: Grifols
-
Manufacturer Copay Assistance: No
-
Product Assistance Program: No
-
-
Product: Rixubis
-
Average Adult Half-life: 26.7 hours
-
Administration: Intravenous
-
First Approved in US: 2013
-
Derived From Human Blood: No
-
Derived From: Chinese Hamster Ovary (CHO) cells
-
Manufacturer: Takeda
-
Manufacturer Copay Assistance: $20,000
-
Product Assistance Program: Yes
-
Sub Q
Qfitlia
-
Dosing Frequency: Every 1 or 2 months
-
Administration: Subcutaneous Injection
-
First Approve: 2025
-
Inhibitor Indication: Indicated for both inhibitors and non-inhibitor patients.
-
Derived From Human Blood: No
-
Type: mRNA
-
Manufacturer: Sanofi
-
Manufacturer Copay Assistance: $20000
-
Manufacturer Product Assistance Program: Yes
Alhemo
-
Dosing Frequency: Daily
-
Administration: Subcutaneous Injection
-
First Approve: 2024
-
Inhibitor Indication: Indicated for inhibitors patients only.
-
Derived From Human Blood: No
-
Type: Monoclonal Antibody
-
Manufacturer: Novo Nordisk
-
Manufacturer Copay Assistance: $15000
-
Manufacturer Product Assistance Program: Yes
Hympavzi
-
Dosing Frequency: Every 7 days
-
Administration: Subcutaneous Injection
-
First Approve: 2024
-
Inhibitor Indication: Indicated for non-inhibitor patients only.
-
Derived From Human Blood: No
-
Type: Monoclonal Antibody
-
Manufacturer: Pfizer
-
Manufacturer Copay Assistance: $15000
-
Manufacturer Product Assistance Program: Yes
Gene Therapy
Hemgenix
-
Product: Hemgenix
-
Average Factor IX at 2 Years: 37%
-
Administration: One time infusion
-
Pre-existing antibodies to adeno-associated virus serotype 5 accessibility: Acceptable. Patients that test positive for adeno-associated virus serotype 5 antibodies may still be able to receive Hemgenix.
-
Derived From Human Blood: No
-
Gene Therapy Type: Adeno-associated virus vector-based (AAV5)
-
Manufacturer: CSL Behring
-
First Approved in US: 2022
-
Manufacturer Financial Assistance Program: Yes
VWD
-
Product: Humate-P
-
Average Adult Half-life: Factor VIII 12.2 hours
VWD 11 hours -
Administration: Intravenous
-
First Approved in US: 1986
-
Derived From Human Blood: Yes
-
Derived From: Human Plasma
-
Manufacturer: CSL Behring
-
Manufacturer Copay Assistance: $12,000
-
Product Assistance Program: Yes
-
-
Product: VonVendi
-
Average Adult Half-life: VWD 19.1-22.6 hours dependent upon dosing
-
Administration: Intravenous
-
First Approved in US: 2015
-
Derived From Human Blood: No
-
Derived From: Chinese Hamster Ovary (CHO) cells
-
Manufacturer: Takeda
-
Manufacturer Copay Assistance: $20,000
-
Product Assistance Program: Yes
-
-
Product: Wilate
-
Average Adult Half-life: 10.6 hours
-
Administration: Intravenous
-
First Approved in US: 2009
-
Derived From Human Blood: No
-
Derived From: Human Plasma
-
Manufacturer: Octapharma
-
Manufacturer Copay Assistance: $12,000
-
Product Assistance Program: Yes
-
-
Product: Alphanate
-
Average Adult Half-life: Factor VIII 17.9 hours
VWD 7.7 hours -
Administration: Intravenous
-
First Approved in US: 1978
-
Derived From Human Blood: No
-
Derived From: Human Plasma
-
Manufacturer: GRIFOLS
-
Manufacturer Copay Assistance: For previously enrolled patients only
-
Product Assistance Program: Yes
-
Factor X
-
Product: Coagadex
-
Average Adult Half-life: 30.3 hours
-
Administration: Intravenous
-
First Approved in US: 2015
-
Derived From Human Blood: Yes
-
Derived From: Human Plasma
-
Manufacturer: Kedrion
-
Manufacturer Copay Assistance: $12,000
-
Product Assistance Program: No
-
Fibrin Stabilizing Factor Deficiency/Factor XIII (13) Deficiency
-
Product: Tretten
-
Average Adult Half-life: 5.1 days
-
Administration: Intravenous
-
First Approved in US: 2013
-
Derived From Human Blood: No
-
Derived From: Saccharomyces Cerevisiae
-
Manufacturer: Novo Nordisk
-
Manufacturer Copay Assistance: $15,000
-
Product Assistance Program: Yes
-
-
Product: Corifact
-
Average Adult Half-life: 7.1 days
-
Administration: Intravenous
-
First Approved in US: 2011
-
Derived From Human Blood: Yes
-
Derived From: Human Plasma
-
Manufacturer: CSL Behring
-
Manufacturer Copay Assistance: No
-
Product Assistance Program: Yes
-
Hemophilia A with Inhibitors
-
Product: Novoseven RT
-
Average Adult Half-life: 2-3 hours
-
Administration: Intravenous
-
First Approved in US: 1999
-
Derived From Human Blood: No
-
Derived From: Baby Hamster Kidney (BHK) cell line
-
Manufacturer: Novo Nordisk
-
Manufacturer Copay Assistance: $15,000
-
Product Assistance Program: Yes
-
-
Product: SevenFACT
-
Average Adult Half-life: 1.6 hours
-
Administration: Intravenous
-
First Approved in US: 2020
-
Derived From Human Blood: No
-
Derived From: Genetically Engineered Rabbit's Milk
-
Manufacturer: HEMA Biologics
-
Manufacturer Copay Assistance: $12,000
-
Product Assistance Program: Yes
-
-
Product: Feiba
-
Average Adult Half-life: "The pharmacokinetic properties of FEIBA have not been formally studied in humans." Every 6-12 hours dosing
-
Administration: Intravenous
-
First Approved in US: 1986
-
Derived From Human Blood: Yes
-
Derived From: Human Plasma
-
Manufacturer: Takeda
-
Manufacturer Copay Assistance: $20,000
-
Product Assistance Program: Yes
-
Alexander’s Disease/Factor VII (7) Deficiency
-
Product: Novoseven RT
-
Average Adult Half-life: 2-3 hours
-
Administration: Intravenous
-
First Approved in US: 1999
-
Derived From Human Blood: No
-
Derived From: Baby Hamster Kidney (BHK) cell line
-
Manufacturer: Novo Nordisk
-
Manufacturer Copay Assistance: $15,000
-
Product Assistance Program: Yes
-
Fibrinogen Deficiency/Factor I (1) Deficiency
-
Product: RiaSTAP
-
Average Adult Half-life: 82.3 hours
-
Administration: Intravenous
-
First Approved in US: 2009
-
Derived From Human Blood: Yes
-
Derived From: Human Plasma
-
Manufacturer: CSL Behring
-
Manufacturer Copay Assistance: No
-
Product Assistance Program: Yes
-
-
Product: FIBRYGA
-
Average Adult Half-life: 75.9 hours
-
Administration: Intravenous
-
First Approved in US: 2017
-
Derived From Human Blood: Yes
-
Derived From: Human Plasma
-
Manufacturer: Octapharma
-
Manufacturer Copay Assistance: $2,500
-
Product Assistance Program: Yes
-
Plasminogen Deficiency
-
Product: RYPLAZIM
-
Average Adult Half-life: 34 hours
-
Administration: Intravenous
-
First Approved in US: 2021
-
Derived From Human Blood: Yes
-
Derived From: Human Plasma
-
Manufacturer: Kedrion
-
Manufacturer Copay Assistance: $20,000
-
Product Assistance Program: No
-
Acquired Thrombotic Thrombocytopenic Purpura (aTTP)
-
Product: Cablivi
-
Average Adult Half-life: "The half-life of Cablivi is concentration and target-level dependent."
-
Administration: Intravenous and Subcutaneous
-
First Approved in US: 2019
-
Derived From Human Blood: No
-
Derived From: Escherichia Coli
-
Manufacturer: Sanofi
-
Manufacturer Copay Assistance: $25,000
-
Product Assistance Program: Yes
-
